Taysha Gene Therapies Overview
Get informed when a big investor buys or sells
+ Follow-10.25
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
Taysha Gene Therapies's p/e ratio stands at -10.25. That is below the Healthcare sector average of 22.57. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.
Taysha Gene Therapies sits lower the Healthcare benchmark (22.57) with a P/E ratio of -10.25. That is roughly 145.4% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.
Whether -10.25 is attractive depends on Taysha Gene Therapies's earnings outlook, competitive position, and how peers are valued. Investors typically ask: is growth accelerating, are margins stable, and is the multiple expanding or compressing over time? The history and comparison charts below are built for those checks.
The history chart shows how Taysha Gene Therapies's P/E ratio evolved across reporting periods, while the comparison chart places TSHA next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.
Yes — within Healthcare, P/E ratio is commonly used to spot outliers. Taysha Gene Therapies's reading of -10.25 (sector avg 22.57) is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.
